Twice daily tRT by IMRT compasred with SIB IRT with concurrent chemotherapy

Long term Survival & Competing Rsks of Death in the ESPATUE Randomized Phase III

Impact of radiation dose to the immune cells in unresectable or stage III

Exposure of the heart in lung cancer radiation therapy A Systematic review

Panel Discussion - Local Therapy Locally Advanced

Nivolumab + Chemotherapy Vs Chemotherapy as NAT in Resectable Stage III

Overall survival & Biomarker analysis of Neoadjuvant Nivolumab Plus Chemotherapy

Pre treatment ctDNA Levels Significantly Predicts of OS & PFS in NADIM II Trial

Sugemalimab vs Placebo after cCRT or sCRT in Patients with Unresectable stage III

Consolidation nivolumab plus ipilimumab or nivolumab alone following

Proton therapy & concurrent Chemotherapy in stage III NSCLC

Concurrent versus sequential immune checkpoint inhibition in stage III NSCLC

Impact of grade 2 Pneumonitis on Patient Reported outcomes with Durvalumab

Association of Driver Oncogene Variations with Outcomes in Patients

Panel Discussion - Durvalumab in Stage III NSCLC

Twice daily tRT by IMRT compasred with SIB IRT with concurrent chemotherapy

Long term Survival & Competing Rsks of Death in the ESPATUE Randomized Phase III

Impact of radiation dose to the immune cells in unresectable or stage III

Exposure of the heart in lung cancer radiation therapy A Systematic review

Panel Discussion - Local Therapy Locally Advanced

Nivolumab + Chemotherapy Vs Chemotherapy as NAT in Resectable Stage III

Overall survival & Biomarker analysis of Neoadjuvant Nivolumab Plus Chemotherapy

Pre treatment ctDNA Levels Significantly Predicts of OS & PFS in NADIM II Trial

Sugemalimab vs Placebo after cCRT or sCRT in Patients with Unresectable stage III

Consolidation nivolumab plus ipilimumab or nivolumab alone following

Proton therapy & concurrent Chemotherapy in stage III NSCLC

Concurrent versus sequential immune checkpoint inhibition in stage III NSCLC

Impact of grade 2 Pneumonitis on Patient Reported outcomes with Durvalumab

Association of Driver Oncogene Variations with Outcomes in Patients

Panel Discussion - Durvalumab in Stage III NSCLC